{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:19:09Z","timestamp":1791393549686,"version":"4.3.3"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004390","name":"Ottawa Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.thromres.2021.11.026","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T08:23:56Z","timestamp":1653553436000},"page":"S66-S71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"S1","title":["Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer"],"prefix":"10.1016","volume":"213","author":[{"given":"Tzu-Fei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.thromres.2021.11.026_bb0005","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2021.11.026_bb0010","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12885-019-6314-9","article-title":"Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study","volume":"19","author":"Jakobsen","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.thromres.2021.11.026_bb0015","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0038-1648229","article-title":"Anticancer drug-related nonvalvular atrial fibrillation: challenges in management and antithrombotic strategies","volume":"44","author":"Tufano","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.thromres.2021.11.026_bb0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2021.11.026_bb0025","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2021.11.026_bb0030","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.thromres.2021.11.026_bb0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.thromres.2021.11.026_bb0040","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis","volume":"134","author":"Carrier","year":"2014","journal-title":"Thromb. Res."},{"issue":"7","key":"10.1016\/j.thromres.2021.11.026_bb0045","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.thromres.2021.11.026_bb0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2021.11.026_bb0055","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.thromres.2021.11.026_bb0060","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.thromres.2021.11.026_bb0065","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"17","key":"10.1016\/j.thromres.2021.11.026_bb0070","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2021.11.026_bb0075","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2021.11.026_bb0080","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2021.11.026_bb0085","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2021.11.026_bb0090","author":"Cancer-Associated Venous Thromboembolic Disease"},{"issue":"4","key":"10.1016\/j.thromres.2021.11.026_bb0095","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.thromres.2021.11.026_bb0100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11239-020-02180-x","article-title":"Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE","volume":"50","author":"Weitz","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"8","key":"10.1016\/j.thromres.2021.11.026_bb0105","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(04)01528-1","article-title":"Drug interactions in oncology","volume":"5","author":"Beijnen","year":"2004","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.thromres.2021.11.026_bb0110","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.critrevonc.2010.05.004","article-title":"Potential drug interactions in elderly cancer patients","volume":"78","author":"Girre","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.thromres.2021.11.026_bb0115","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clgc.2017.07.004","article-title":"Phase I study of dalteparin in combination with sunitinib in patients with metastatic clear cell renal carcinoma","volume":"16","author":"Wentink","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"issue":"6","key":"10.1016\/j.thromres.2021.11.026_bb0120","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/cncr.33337","article-title":"Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin","volume":"127","author":"Patel","year":"2021","journal-title":"Cancer"},{"issue":"49","key":"10.1016\/j.thromres.2021.11.026_bb0125","doi-asserted-by":"crossref","first-page":"37302","DOI":"10.1074\/jbc.M604905200","volume":"281","author":"Zhang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.thromres.2021.11.026_bb0130","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/17425255.2016.1225037","article-title":"Drug-drug interactions of non-vitamin K oral anticoagulants","volume":"12","author":"Voukalis","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.thromres.2021.11.026_bb0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-glycoprotein in pharmacokinetics","volume":"42","author":"Lin","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.thromres.2021.11.026_bb0140","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and induction of cytochrome P450 and the clinical implications","volume":"35","author":"Lin","year":"1998","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.thromres.2021.11.026_bb0145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized evaluation of long-term anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9984","key":"10.1016\/j.thromres.2021.11.026_bb0150","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-factor xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.thromres.2021.11.026_bb0155","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1055\/s-0037-1613679","article-title":"Apixaban-calibrated anti-FXa activity in relation to outcome events and clinical characteristics in patients with atrial fibrillation: results from the AVERROES trial","volume":"1","author":"Bhagirath","year":"2017","journal-title":"TH Open"},{"issue":"1","key":"10.1016\/j.thromres.2021.11.026_bb0160","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.thromres.2021.11.026_bb0165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2018-08-835595","article-title":"How I treat cancer-associated venous thromboembolism","volume":"133","author":"Kraaijpoel","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2021.11.026_bb0170","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.thromres.2021.11.026_bb0175","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620936325","article-title":"drug-drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants: a comprehensive review of interactions and mechanisms","volume":"26","author":"Peixoto de Miranda","year":"2020","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2021.11.026_bb0180","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejca.2021.02.026","article-title":"Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism","volume":"148","author":"Verso","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.thromres.2021.11.026_bb0185","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1111\/jth.15367","article-title":"Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: communication from the ISTH SSC subcommittee on hemostasis and malignancy","volume":"19","author":"Wang","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"26","key":"10.1016\/j.thromres.2021.11.026_bb0190","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2021.11.026_bb0195","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2021.11.026_bb0205","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jamainternmed.2020.1835","article-title":"Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants","volume":"180","author":"Hill","year":"2020","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"10.1016\/j.thromres.2021.11.026_bb0210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00228-020-03015-7","article-title":"Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a swedish, register-based cohort study in atrial fibrillation outpatients","volume":"77","author":"Holm","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.thromres.2021.11.026_bb0215","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10557-019-06907-8","article-title":"Impact of polypharmacy and P-glycoprotein- and CYP3A4-modulating drugs on safety and efficacy of Oral anticoagulation therapy in patients with atrial fibrillation","volume":"33","author":"Harskamp","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"7","key":"10.1016\/j.thromres.2021.11.026_bb0220","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1177\/1078155220901569","article-title":"Prospective evaluation of drug-drug interactions in ambulatory cancer patients initiated on prophylactic anticoagulation","volume":"26","author":"Ng","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.thromres.2021.11.026_bb0225","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.thromres.2020.08.016","article-title":"Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: a systematic review","volume":"194","author":"Li","year":"2020","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.thromres.2021.11.026_bb0230","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40261-020-00982-8","article-title":"Concomitant use of direct oral anticoagulants and antiepileptic drugs: a prospective cohort study in patients with atrial fibrillation","volume":"41","author":"Giustozzi","year":"2021","journal-title":"Clin. Drug Investig."},{"issue":"8","key":"10.1016\/j.thromres.2021.11.026_bb0235","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-021-00844-7","article-title":"Correction to: effect of EnzymeInducing antiseizure medications on the risk of SubTherapeutic concentrations of direct oral anticoagulants: a retrospective cohort study","volume":"35","author":"Perlman","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.thromres.2021.11.026_bb0240","unstructured":"Enzalutamide (Xtandi), product monograph. https:\/\/www.astellas.com\/ca\/system\/files\/pdf\/Xtandi_PM_EN.pdf."},{"key":"10.1016\/j.thromres.2021.11.026_bb0245","unstructured":"Apalutamide (Erleada), product monograph. https:\/\/pdf.hres.ca\/dpd_pm\/00046215.PDF."},{"key":"10.1016\/j.thromres.2021.11.026_bb0250","unstructured":"Abiraterone (Zytiga) product monograph. https:\/\/pdf.hres.ca\/dpd_pm\/00044223.PDF."},{"issue":"7","key":"10.1016\/j.thromres.2021.11.026_bb0255","first-page":"833","article-title":"A study on drug interaction between warfarin and capecitabine with special reference to the co-administered term or the discontinuation term of capecitabine","volume":"42","author":"Ikenishi","year":"2015","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.thromres.2021.11.026_bb0260","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13046-015-0201-2","article-title":"A pilot study on the impact of known drug-drug interactions in cancer patients","volume":"34","author":"Ussai","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.thromres.2021.11.026_bb0265","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-020-02135-2","article-title":"Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation","author":"Wang","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"issue":"9","key":"10.1016\/j.thromres.2021.11.026_bb0270","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2021.11.026_bb0275","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2021.11.026_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482100548X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482100548X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:49:31Z","timestamp":1758736171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938482100548X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":55,"alternative-id":["S004938482100548X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2021.11.026","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2021.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}